DRIVEN BRANDS DEADLINE ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Driven Brands To Contact Him Directly To Discuss Their Options
January 17, 2024 09:45 ET
|
Faruqi & Faruqi LLP
If you suffered losses exceeding $100,000 investing in Driven Brands stock or options between October 27, 2021 and August 1, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi...
LOVESAC SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Lovesac To Contact Him Directly To Discuss Their Options
January 17, 2024 09:45 ET
|
Faruqi & Faruqi LLP
If you suffered losses exceeding $50,000 investing in Lovesac stock or options between March 30, 2023 and August 16, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
ESTEE SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Estee To Contact Him Directly To Discuss Their Options
January 17, 2024 09:45 ET
|
Faruqi & Faruqi LLP
If you suffered losses exceeding $100,000 investing in Estee stock or options between August 18, 2022 and May 2, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
LIVEPERSON SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In LivePerson To Contact Him Directly To Discuss Their Options
January 17, 2024 09:45 ET
|
Faruqi & Faruqi LLP
If you suffered losses exceeding $50,000 investing in LivePerson stock or options between May 10, 2022 and March 16, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Data Catalog Market Expected to Reach US$3,467.1 Million by 2030, with a 20.2% CAGR - Persistence Market Research
January 17, 2024 09:45 ET
|
Persistence Market Research
New York, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Market Size & Overview: The global data catalog market is forecast to expand at a CAGR of 20.2% and thereby increase from a value of US$956.4...
EAGLE PHARMACEUTICALS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
January 17, 2024 09:45 ET
|
Faruqi & Faruqi LLP
If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi...
MERCURY SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mercury to Contact Him Directly to Discuss Their Options
January 17, 2024 09:45 ET
|
Faruqi & Faruqi LLP
If you suffered losses exceeding $100,000 investing in Mercury stock or options between December 7, 2020 and June 23, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Net Asset Value(s)
January 17, 2024 09:45 ET
|
Octopus AIM VCT PLC
Octopus AIM VCT plc Net Asset Value Octopus AIM VCT plc announces that as at 15 January 2024 the unaudited net asset value of the Ordinary shares was approximately 63.0 pence per share. For further...
Net Asset Value(s)
January 17, 2024 09:45 ET
|
Octopus AIM VCT 2 plc
Octopus AIM VCT 2 plc Net Asset Value Octopus AIM VCT 2 plc announces that as at 15 January 2024 the unaudited net asset value of the Ordinary shares was approximately 48.5 pence per share. For...
Egypt Remittance Market Sees Notable Growth in 2023 with Forecasts to 2028: Inbound and Outbound Transaction Trends Analyzed
January 17, 2024 09:43 ET
|
Research and Markets
Dublin, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The "Egypt International Remittance Market Business and Investment Opportunities - Analysis by Transaction Value & Volume, Inbound and Outbound...
- July 24, 2024 11:16 ET Global Insulin Pen Market Poised for Expansion, Projected to Reach US$ 10.71 Billion by 2032, Fueled by Technological Advancements and User-Friendly Designs and International Prevalence of Diabetes
- July 24, 2024 11:15 ET NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors